HYTN Awarded Medical Cannabis Sales License By Health Canada

Author: Vuk Zdinjak | August 23, 2022 09:49am

HYTN Cannabis Inc., wholly owned subsidiary of HYTN Innovations Inc. (CSE:HYTN) has been awarded a license by Health Canada allowing for the sale of cannabis for medical purposes. This follows a list of license achievements including a standard processing license, cannabis research license, an amendment for sale of recreational cannabis and a standard cannabis cultivation license at the company’s Kelowna production facility.

"Achieving this license ensures that HYTN will be well positioned to capitalize on cannabis opportunities as they arise without lengthy licensing periods influencing our decision making. Having our production facility hold all available cannabis licenses demonstrates the strength of our regulatory program, operations and team and will allow us to evaluate revenue streams, including medical sales prospects, that run parallel to our core business," stated Elliot McKerr, HYTN CEO.

"Transitioning from our partnership with Emerald Health Therapeutics (OTCQB:EMHTF) (CSE:EMH) has highlighted the extended time cannabis companies may wait while navigating the complex regulatory environment, and although HYTN is focused on its core business, this amendment allows us to evaluate medical sales prospects with an immediate degree of commercial certainty," continued McKerr.

Jason Broome, HYTN COO, stated, "While HYTN's focus has been on recreational cannabis products for the Canadian market, we have also demonstrated our ability to build on that foundation and develop, and commercialize medical products for export. We are confident we can continue to execute on medical projects as opportunities arise and the License simply enhances our ability to do so."

Photo: Benzinga; Sources: courtesy of Matthias Zomer via Pexels, squarefrog via Pixabay

 

 

Posted In: CSE:EMH CSE:HYTN EMHTF